Enliven Therapeutics Inc (NAS:ELVN)

$ 20.44 -0.49 (-2.34%) Market Cap: 961.43 Mil Enterprise Value: 664.23 Mil PE Ratio: 0 PB Ratio: 3.08 GF Score: 22/100

Enliven Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Enliven Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Enliven Therapeutics Inc and Imara Inc Announce Merger Agreement-M&A Call Transcript
Oct 13, 2022
Q3 2021 Imara Inc Earnings Call Transcript
Nov 09, 2021

Earnings
Q2 2021 Imara Inc Earnings Call Transcript
Aug 06, 2021

Earnings
Q1 2021 Imara Inc Earnings Call Transcript
May 11, 2021

Earnings
Q4 2020 Imara Inc Earnings Call Transcript
Mar 05, 2021

Earnings
Q3 2020 Imara Inc Earnings Call Transcript
Nov 05, 2020

Earnings
Eiger BioPharmaceuticals Inc, Applied Therapeutics, Ultragenyx Pharmaceutical, Dicerna Pharmaceuticals, and Imara Inc at Citi BioPharma Conference (Virtual) - Panel Transcript
Sep 09, 2020
Q2 2020 Imara Inc Earnings Call Transcript
Aug 14, 2020

Earnings

Enliven Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 03:00PM GMT

Release Date Price: $20 (-2.44%)

Transcript

Salveen Richter

Goldman Sachs Group, Inc. - Analyst

Good morning, everyone, and thanks so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. I'm really pleased to have with us Sam Kintz, Co-Founder and CEO of Enliven.

Questions & Answers

Salveen Richter

Goldman Sachs Group, Inc. - Analyst

So with that, Sam, just for those not familiar with the Enliven story, perhaps you could just give us a brief overview of the company, your pipeline, upcoming milestones, and strategy.

Sam Kintz

Enliven Therapeutics, Inc. - Co-Founder, CEO, & Board Member

Absolutely. Thanks for having me, Salveen, and thanks to you guys for joining. So yeah, Enliven is a precision oncology company. We're early clinical stage, and we have some of -- I think, some of the best R&D leaders in the small molecule precision oncology space, including Joe Lyssikatos, Co-Founder and Chief Scientific Officer, who's probably best well known for starting and building the Array Biopharma internal programs group

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.